StockData
Veru Inc. logo

Veru Inc. (VERU) stock

VERUNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 10, 2026Score 6/30
$2.14+0.06 (+2.88%)

Close on Nov 17, 2026Market cap $36.49MP/E –Yield –

Veru r&d expenses

Research and development expenses are spending on new products and technology.

Veru's R&D Expenses for the twelve months ending Jun 30, 2026 was $11.76M, down 26.3% year over year. For fiscal 2025 it was $15.59M, up 22.0% from the year before. Over ten years it grew 53.1% a year on average. The highest annual figure on record is $70.91M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Sep 30, 2025$15.59M+22.0%
FY2024Sep 30, 2024$12.78M-75.0%
FY2023Sep 30, 2023$51.20M-27.8%
FY2022Sep 30, 2022$70.91M+116.9%
FY2021Sep 30, 2021$32.69M+93.1%
FY2020Sep 30, 2020$16.94M+23.2%
FY2019Sep 30, 2019$13.74M+26.7%
FY2018Sep 30, 2018$10.85M+252.7%
FY2017Sep 30, 2017$3.08M+2995.2%
FY2016Sep 30, 2016$99.39K-54.8%
FY2015Sep 30, 2015$219.82K+3842.9%
FY2014Sep 30, 2014$5.58K+17.5%
FY2013Sep 30, 2013$4.75K-10.1%
FY2012Sep 30, 2012$5.28K-51.7%
FY2011Sep 30, 2011$10.93K+2768.5%
FY2010Sep 30, 2010$381-99.6%
FY2009Sep 30, 2009$105.92K–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

Periods
PeriodPeriod endValueChange
Q3 FY2026CQ2 2026Jun 30, 2026$4.35M+44.1%
Q2 FY2026CQ1 2026Mar 31, 2026$3.15M-20.0%
Q1 FY2026CQ4 2025Dec 31, 2025$1.34M-76.5%
Q4 FY2025CQ3 2025Sep 30, 2025$2.92M-11.3%
Q3 FY2025CQ2 2025Jun 30, 2025$3.02M-37.7%
Q2 FY2025CQ1 2025Mar 31, 2025$3.93M+31.7%
Q1 FY2025CQ4 2024Dec 31, 2024$5.72M+244.7%
Q4 FY2024CQ3 2024Sep 30, 2024$3.29M-16.5%
Q3 FY2024CQ2 2024Jun 30, 2024$4.85M-44.9%
Q2 FY2024CQ1 2024Mar 31, 2024$2.99M-83.3%
Q1 FY2024CQ4 2023Dec 31, 2023$1.66M-92.0%
Q4 FY2023CQ3 2023Sep 30, 2023$3.94M-85.5%
Q3 FY2023CQ2 2023Jun 30, 2023$8.79M-51.5%
Q2 FY2023CQ1 2023Mar 31, 2023$17.86M+14.9%
Q1 FY2023CQ4 2022Dec 31, 2022$20.61M+104.5%
Q4 FY2022CQ3 2022Sep 30, 2022$27.16M+228.9%
Q3 FY2022CQ2 2022Jun 30, 2022$18.13M+62.1%
Q2 FY2022CQ1 2022Mar 31, 2022$15.54M+105.2%
Q1 FY2022CQ4 2021Dec 31, 2021$10.08M+77.6%
Q4 FY2021CQ3 2021Sep 30, 2021$8.26M+152.6%
Q3 FY2021CQ2 2021Jun 30, 2021$11.19M+152.2%
Q2 FY2021CQ1 2021Mar 31, 2021$7.57M+92.7%
Q1 FY2021CQ4 2020Dec 31, 2020$5.68M+7.1%
Q4 FY2020CQ3 2020Sep 30, 2020$3.27M-9.3%
Q3 FY2020CQ2 2020Jun 30, 2020$4.44M-8.8%
Q2 FY2020CQ1 2020Mar 31, 2020$3.93M+35.0%
Q1 FY2020CQ4 2019Dec 31, 2019$5.30M+124.4%
Q4 FY2019CQ3 2019Sep 30, 2019$3.61M+19.1%
Q3 FY2019CQ2 2019Jun 30, 2019$4.87M+28.5%
Q2 FY2019CQ1 2019Mar 31, 2019$2.91M+40.1%
Q1 FY2019CQ4 2018Dec 31, 2018$2.36M+20.6%
Q4 FY2018CQ3 2018Sep 30, 2018$3.03M+116.4%
Q3 FY2018CQ2 2018Jun 30, 2018$3.79M+1153.9%
Q2 FY2018CQ1 2018Mar 31, 2018$2.08M+72.0%
Q1 FY2018CQ4 2017Dec 31, 2017$1.96M+1044.6%
Q4 FY2017CQ3 2017Sep 30, 2017$1.40M+42891.1%
Q3 FY2017CQ2 2017Jun 30, 2017$302.07K–
Q2 FY2017CQ1 2017Mar 31, 2017$1.21M–
Q1 FY2017CQ4 2016Dec 31, 2016$171.10K–
Q4 FY2016CQ3 2016Sep 30, 2016$3.26K–

More Veru figures

See a number that looks wrong?